Premium
Irreversible Inhibitors of the Epidermal Growth Factor Receptor: Thienopyrimidine Core with α,β‐Unsaturated Amide Side Chain
Author(s) -
Yang Xiu L.,
Wang Tian C.,
Lin Sen,
Fan Hou X.
Publication year - 2014
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201400098
Subject(s) - chemistry , epidermal growth factor receptor , lapatinib , stereochemistry , tyrosine kinase , side chain , receptor tyrosine kinase , enzyme , amide , kinase , biochemistry , receptor , medicine , cancer , trastuzumab , organic chemistry , breast cancer , polymer
Overexpression of epidermal growth factor receptor (EGFR) tyrosine kinases has been found in a variety of cancers such as breast, ovarian, colon, and non‐small‐cell lung cancers, which is associated with poor prognosis in patients. In an effort to find effective irreversible inhibitors of the EGFR tyrosine kinase family (mainly HER2), two series of HER2 tyrosine kinase inhibitors with thieno[3,2‐ d ]pyridine and thieno[2,3‐ d ]pyridine as central part and with a basic α,β‐unsaturated amide side chain were developed. The α,β‐unsaturated amide side chain (the Michael acceptor) at the 6‐position, which forms a covalent bond to Cys773 located in the ATP binding pocket of the EGFR enzyme, is a major factor in the generation of irreversible inhibition. In our study, thienopyrimidine instead of quinazoline was used as the central structure, and different substituents were introduced at the 4‐position to investigate the structure–activity relationships. The thieno[2,3‐ d ]pyrimidine derivatives 16a – d showed potent HER2 enzyme inhibition and anti‐proliferative activity against SK‐BR‐3 cells. Especially, ( E )‐ N ‐(4‐((3‐chloro‐4‐(pyridin‐2‐ylmethoxy)phenyl)amino)thieno[2,3‐ d ]pyrimidin‐6‐yl)‐4‐(dimethylamino)but‐2‐enamide 16d was identified as a potential irreversible HER2 inhibitor. Both its catalytic enzyme activity profile and its cellular efficacy were found to be superior to those of the marketed drug lapatinib.